UA130106C2 - Мультиспецифічні зв'язувальні білки для лікування раку - Google Patents
Мультиспецифічні зв'язувальні білки для лікування ракуInfo
- Publication number
- UA130106C2 UA130106C2 UAA202201295A UAA202201295A UA130106C2 UA 130106 C2 UA130106 C2 UA 130106C2 UA A202201295 A UAA202201295 A UA A202201295A UA A202201295 A UAA202201295 A UA A202201295A UA 130106 C2 UA130106 C2 UA 130106C2
- Authority
- UA
- Ukraine
- Prior art keywords
- amino acid
- acid sequence
- heavy chain
- variable domain
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19201200 | 2019-10-02 | ||
| PCT/EP2020/077586 WO2021064137A2 (en) | 2019-10-02 | 2020-10-01 | Multi-specific binding proteins for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130106C2 true UA130106C2 (uk) | 2025-11-12 |
Family
ID=68136317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202201295A UA130106C2 (uk) | 2019-10-02 | 2020-10-01 | Мультиспецифічні зв'язувальні білки для лікування раку |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11732045B2 (https=) |
| EP (1) | EP4038100A2 (https=) |
| JP (2) | JP7387885B2 (https=) |
| KR (1) | KR20220075383A (https=) |
| CN (1) | CN114641496B (https=) |
| AR (1) | AR120138A1 (https=) |
| AU (1) | AU2020358893A1 (https=) |
| BR (1) | BR112022004047A2 (https=) |
| CA (1) | CA3153372A1 (https=) |
| CL (1) | CL2022000664A1 (https=) |
| CO (1) | CO2022003552A2 (https=) |
| CR (1) | CR20220136A (https=) |
| DO (1) | DOP2022000060A (https=) |
| EC (1) | ECSP22019193A (https=) |
| IL (1) | IL291817A (https=) |
| JO (1) | JOP20220079A1 (https=) |
| MX (1) | MX2022004042A (https=) |
| MY (1) | MY209387A (https=) |
| PE (1) | PE20221412A1 (https=) |
| PH (1) | PH12022550693A1 (https=) |
| SA (1) | SA522432139B1 (https=) |
| TW (1) | TWI878355B (https=) |
| UA (1) | UA130106C2 (https=) |
| WO (1) | WO2021064137A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| CN114395043B (zh) * | 2021-12-07 | 2023-07-11 | 合肥天港免疫药物有限公司 | Ncr3lg1抗体及其应用 |
| CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| CN114395045B (zh) * | 2021-12-07 | 2023-06-09 | 合肥天港免疫药物有限公司 | B7h6抗体及其应用 |
| WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| CA3266173A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| JP2026512969A (ja) | 2022-10-26 | 2026-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇを活性化することができる複素環式化合物 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731A (en) | 1848-08-22 | Elisha k | ||
| US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69305085D1 (de) | 1992-08-10 | 1996-10-31 | Alcan Aluminium Ltd | Geländer |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| NL1019562C2 (nl) | 2001-12-13 | 2003-06-17 | Heineken Tech Services | Klepsamenstel voor gebruik bij drankafgifte. |
| US8764654B2 (en) | 2008-03-19 | 2014-07-01 | Zin Technologies, Inc. | Data acquisition for modular biometric monitoring system |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| CN102099055A (zh) | 2007-10-04 | 2011-06-15 | 津莫吉尼蒂克斯公司 | B7家族成员zB7H6及相关的组合物和方法 |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| FI20090280A7 (fi) | 2009-07-17 | 2011-01-18 | Kone Corp | Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa |
| KR101721187B1 (ko) | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
| KR102060389B1 (ko) * | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| AU2012323287B2 (en) * | 2011-10-10 | 2018-02-01 | Xencor, Inc. | A method for purifying antibodies |
| WO2013169691A1 (en) * | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| IN2015DN01299A (https=) * | 2012-07-23 | 2015-07-03 | Zymeworks Inc | |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2017181001A1 (en) * | 2016-04-15 | 2017-10-19 | Trustees Of Dartmouth College | High affinity b7-h6 antibodies and antibody fragments |
| RS61510B1 (sr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2020
- 2020-09-30 TW TW109134076A patent/TWI878355B/zh active
- 2020-10-01 MX MX2022004042A patent/MX2022004042A/es unknown
- 2020-10-01 JP JP2022520371A patent/JP7387885B2/ja active Active
- 2020-10-01 MY MYPI2022001742A patent/MY209387A/en unknown
- 2020-10-01 UA UAA202201295A patent/UA130106C2/uk unknown
- 2020-10-01 PH PH1/2022/550693A patent/PH12022550693A1/en unknown
- 2020-10-01 IL IL291817A patent/IL291817A/en unknown
- 2020-10-01 AU AU2020358893A patent/AU2020358893A1/en active Pending
- 2020-10-01 PE PE2022000468A patent/PE20221412A1/es unknown
- 2020-10-01 KR KR1020227014608A patent/KR20220075383A/ko active Pending
- 2020-10-01 EP EP20789508.7A patent/EP4038100A2/en active Pending
- 2020-10-01 AR ARP200102733A patent/AR120138A1/es unknown
- 2020-10-01 WO PCT/EP2020/077586 patent/WO2021064137A2/en not_active Ceased
- 2020-10-01 BR BR112022004047A patent/BR112022004047A2/pt unknown
- 2020-10-01 US US17/060,111 patent/US11732045B2/en active Active
- 2020-10-01 CR CR20220136A patent/CR20220136A/es unknown
- 2020-10-01 CA CA3153372A patent/CA3153372A1/en active Pending
- 2020-10-01 CN CN202080068909.4A patent/CN114641496B/zh active Active
-
2022
- 2022-01-31 JO JOP/2022/0079A patent/JOP20220079A1/ar unknown
- 2022-03-14 EC ECSENADI202219193A patent/ECSP22019193A/es unknown
- 2022-03-18 DO DO2022000060A patent/DOP2022000060A/es unknown
- 2022-03-18 CL CL2022000664A patent/CL2022000664A1/es unknown
- 2022-03-25 CO CONC2022/0003552A patent/CO2022003552A2/es unknown
- 2022-03-31 SA SA522432139A patent/SA522432139B1/ar unknown
-
2023
- 2023-06-20 US US18/337,693 patent/US20230340130A1/en active Pending
- 2023-11-15 JP JP2023194494A patent/JP7809680B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4038100A2 (en) | 2022-08-10 |
| US11732045B2 (en) | 2023-08-22 |
| AR120138A1 (es) | 2022-02-02 |
| SA522432139B1 (ar) | 2024-08-29 |
| US20230340130A1 (en) | 2023-10-26 |
| PH12022550693A1 (en) | 2023-03-27 |
| CN114641496B (zh) | 2026-01-02 |
| CR20220136A (es) | 2022-05-27 |
| PE20221412A1 (es) | 2022-09-20 |
| MY209387A (en) | 2025-07-07 |
| CA3153372A1 (en) | 2021-04-08 |
| TW202128756A (zh) | 2021-08-01 |
| CL2022000664A1 (es) | 2023-01-06 |
| KR20220075383A (ko) | 2022-06-08 |
| IL291817A (en) | 2022-06-01 |
| ECSP22019193A (es) | 2022-04-29 |
| JP2022551081A (ja) | 2022-12-07 |
| JOP20220079A1 (ar) | 2023-01-30 |
| US20210107983A1 (en) | 2021-04-15 |
| JP7387885B2 (ja) | 2023-11-28 |
| BR112022004047A2 (pt) | 2022-05-24 |
| JP2024020414A (ja) | 2024-02-14 |
| JP7809680B2 (ja) | 2026-02-02 |
| WO2021064137A2 (en) | 2021-04-08 |
| MX2022004042A (es) | 2022-05-02 |
| TWI878355B (zh) | 2025-04-01 |
| DOP2022000060A (es) | 2022-05-31 |
| WO2021064137A3 (en) | 2021-05-14 |
| CO2022003552A2 (es) | 2022-04-19 |
| CN114641496A (zh) | 2022-06-17 |
| AU2020358893A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA130106C2 (uk) | Мультиспецифічні зв'язувальні білки для лікування раку | |
| AU2020200751B2 (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP6845905B2 (ja) | Ｐｄ１および／またはｌａｇ３結合性物質 | |
| US20240228635A9 (en) | Ccr8 antibody and application thereof | |
| TWI659042B (zh) | 雙特異性異質二聚體雙功能抗體及彼等之用途 | |
| JP5856073B2 (ja) | Ｒｏｎ結合構築体およびその使用方法 | |
| BR112020022898A2 (pt) | anticorpos biespecíficos dll3-cd3 | |
| WO2019195409A1 (en) | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams | |
| WO2019174603A1 (zh) | 靶向ctla-4抗体、其制备方法和用途 | |
| CN112969716B (zh) | 抗pd-1抗体、其抗原结合片段及医药用途 | |
| TW201726741A (zh) | Ctla4結合劑 | |
| ES2833010T9 (es) | Anticuerpos y receptores de antígenos quiméricos específicos para CD19 | |
| EP4269437A1 (en) | Pd-1 binding molecule and application thereof | |
| CN103864932A (zh) | 拮抗抑制血管内皮细胞生长因子与其受体结合的单克隆抗体及其编码序列与用途 | |
| US20240409645A1 (en) | Binding Molecules Targeting IL-2 Receptor | |
| EP4524156A1 (en) | Fusion protein of relaxin or analogue and medical use thereof | |
| KR20240142592A (ko) | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 | |
| US12275798B2 (en) | Tri-specific binding molecules | |
| CN116601167A (zh) | 鸟苷酸环化酶c(gcc)抗原结合剂的组合物及其使用方法 | |
| CN115181180B (zh) | 抗人程序性死亡配体-1（pd-l1）的抗体及其应用 | |
| CN120659811A (zh) | 双特异性抗原结合分子及其应用 | |
| CN119661712A (zh) | 特异性结合tnfr2的抗体及其应用 | |
| CN120040591A (zh) | 靶向叶酸受体α的全人源抗体多肽片段及其应用 | |
| HK40051455A (en) | Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof |